DprE1-IN-9

• UNSPSC Description:

  DprE1-IN-9 (compound B18) is an effective reversible DprE1 inhibitor and can bind to the receptor cavity of DprE1. DprE1-IN-9 shows strong antimycobacterial activity not only against non-pathogenic strain H37Ra (MIC=0.18 µg/mL) but also against pathogenic H37Rv and the clinical MDR and XDR isolates[1].

• Target Antigen:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/dpre1-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C2OCCN(CC3=NC(C)=C(C)N=C3C)C2=CC(C4CC4)=C1)NCC(F)(F)F

• Molecular Weight:

  434.45

• References & Citations:

  [1]Wang Xiang, et al. Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis. Microbiol Spectr. 2023 Sep 12:e0472122.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2906099-98-5